Details:
The 5 patients in the age group birth to less than 3 months of age were not included in the efficacy analyses since they were enrolled with expanded inclusion criteria and only received the single-dose DALVANCE regimen.
Lead Product(s): Dalbavancin
Therapeutic Area: Infections and Infectious Diseases Product Name: Dalvance
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2021
Details:
Through MOU, Prestige and Vaxine will be building a partnership, initially focused on manufacturing and commercialization of Vaxine’s Covid-19 vaccine, Covax-19® and then as Covid-19 enters an endemic phase development of a next generation Covid19/influenza combo vaccine.
Lead Product(s): Covax-19
Therapeutic Area: Infections and Infectious Diseases Product Name: Spikogen
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Vaxine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2022